Summary
Immunotherapy with interleukin 2 (IL-2) alone or in combination with lymphokine-activated killer cells can mediate tumor regression in mice and in man. Further dose escalation of IL-2 along with lymphokine-activated killer cells has been prevented by the development of a vascular leak syndrome produced by IL-2. Because we have found that interferon α (IFN-α) or tumor necrosis factor (TNF-α) has synergistic antitumor effects when administered together with IL-2, we have tested the vascular leakage induced by these lymphokine combinations. We used a murine model to quantify vascular leakage by measuring the extravasation of 125I-albumin from the intravascular space as well as the wet and dry lung weights after treatment with different cytokines. Cytokines (or Hanks balanced salt solution) were administered to C57BL/6 mice and 4 h after the last injection the vascular leak was quantified. IFN-α alone did not cause extravasation of radiolabel or increase in wet lung weights, though when given in combination with IL-2, significantly greater extravasation (P<0.01) as well as increase in lung water weights (P<0.05) was observed compared to the response in mice treated with IL-2 alone. IFN-α in combination with IL-2 induced significant vascular leakage earlier than the response induced by IL-2 alone. For example treatment with IFN-α and IL-2 induced accumulation of 14674±605 cpm in the lungs at day 1 while IL-2 alone induced 12340±251 cpm. The degree of vascular leakage was highly related to the dose of IFN-α administered along with IL-2 and increased vascular leak syndrome was evident even at low doses (5000 units) of IFN-α. Immunosuppression of mice by pretreatment irradiation (500 rad) markedly decreased the development of vascular leak syndrome induced by IL-2 and IFN-α. Interestingly IFN-γ and TNF-α did not induce vascular leakage in the lungs when given alone, and did not add or synergize with IL-2 in causing the syndrome. Thus the administration of IFN-α in combination with IL-2 produces a dose-limiting vascular leakage that is more severe than that caused by IL-2 alone, and may be mediated, directly or indirectly by host radiosensitive cells.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aguet M, Vignaux F, Fridman WH, Gresser I (1983) Enhancement of Fc receptor expression in interferon-treated mice. Eur J Immunol 11:926
Asher AL, Mule JJ, Rosenberg SA (1987) Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Fed Proc 46:1341
Asher AL, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies of anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963
Bakker WW, Beukhof JR, Van Luijk WH, Van der Hem GK (1982) Vascular permeability increasing factor (VPF) in IgA nephopathy. Clin Nephrol 18:165
Bevilacqua MP, Pober JS, Majeau CR, Fiers W, Cotran RS, Gimbrone MA, Jr (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 83:4533
Brunda MJ, Rosenbaum D (1984) Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 44:597
Brunda MJ, Rosenbaum D, Stern L (1984) Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int J Cancer 34:421
Brunda MJ, Tarnowski D, Davaetlis U (1986) Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int J Cancer 37:787
Brunda MJ, Bellantoni D, Sulich V (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365
Brosjo O, Bauer HCF, Benstrom L, Nilsson OS, Reinholt FP, Tribukait B (1987) Growth inhibition of human osteosarcomas in nude mice by human interferon: significance of dose and tumor differentiation. Cancer Res 47:258
Cameron R, Rosenberg SA (1988) In vivo synergy between interleukin-2 (IL-2) and interferon alpha (IFN) in a murine multiple hepatic model. Faseb J 2: A689 (abstr 2281)
Crane J, Glasgow LA, Kern ER, Younger JS (1978) Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst 61:871
Creasy AA, Reynolds TR, Laired WC (1986) Partial regression of murine and human tumors by recombinant tumor necrosis factor. Cancer Res 46:5687
Dayer JM, Beutler B, Cerami A (1985) Cachetin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162:2163
Ettinghausen SE, Lipford EH, III, Mule JJ, Rosenberg SA (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135:3623
Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80:177
Fidler IJ, Heicappell R, Saiki I, Grutter G, Horisberger MA, Nuesch J (1987) Direct antiproliferative effects of recombinant human interferon-B/D hybrids on human tumor cell lines. Cancer Res 47:2020
Gamble JR, Maslan JM, Kebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667
Geczy CL (1984) The role of lymphokines in delayed-type hypersensitivity reactions. Springer Semin Immunopathol 7:321
Gresser I, Maury C, Brouty-Boye D (1972) Mechanism of the anti tumor effect of interferon in mice. Nature 239:167
Heflin AC, Brigham KL (1981) Prenvention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia. J Clin Invent 68:1253
Heron I, Hokland M, Berg K (1978) Enhanced expression of B-2 microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci 75:6215
Jett JR, Montovani A, Herberman RB (1980) Augmentation of human-monocyte mediated cytolysis by interferon. Cell Immunol 54:425
Kasai M, Iwaniru M, Nagai Y, Okamura K, Tada T (1980) A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 10:175
Kasai M, Yoheda T, Habu S, Maruyama Y, Okumura K, Tokunaga T (1981) In vivo effect of anti-asialo GM1 antibody on natural killer cell activity. Nature 291:334
Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45:3735
Lee SH, Chiu H, Rinderknecht E, Sabo W, Stebbing W (1983) Importance of treatment regimen of interferon as an antitumor agent. Cancer Res 43:4172
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764
Mannel DM, Moore RN, Mergenhagen SE (1980) Macrophages as a source of tumoricidal activity (tumor necrosis factor). Infect Immunol 30:523
Martin WJ, Gadek JE, Hunninghake GW, Crystal RG (1981) Oxidant injury of lung parenchymal cells. J Clin Invest 68:1277
Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159:495
McIntosh J, Mule JJ, Rosenberg SA (1988) Synergistic anti tumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res (in press)
Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Successful adoptive immunotherapy of established pulmonary metastases with lymphokine-activated killer cells and recombinant interleukin-2. Science 225:1487
Mule JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135:646
Nawroth PP, Bank I, Handley D, Cassimiris J, Chess L, Stern D (1986) Tumor necrosis factor-cachetin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 163:1363
Paucker K, Cantell K, Henk W (1962) Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on growth rate of cells. Virology 17:324
Prats I, Rosenberg SA (1988) Synergy of interferon alpha and interleukin-2 in an intradermal model. Proc Am Assoc Cancer Res 29:402 (Abstr 1601)
Quesada JR, Reuben R, Manning RT, Hersh EM, Gutterman J-U (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15
Raj JU, Bland RD (1983) Neutrophil depletion does not prevent oxygen-induced lung injury in rabbits. Chest 83:205
Rehberg E, Kelder B, Hoal EA, Pestka S (1982) Specific molecular activities of recombinant and hybrid leukocyte interferon subtypes. J Biol Chem 257:11497
Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark OF (1984) Biological activity of recombinant human interleukin-2 produced in Escherichia coli Science 223:1412
Rosenbeg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilone E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Special report: observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485
Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889
a. Rosenberg SA, Schwartz S, Spiess P (1988) Combination immunotherapy of cancer: Synergistic anti-tumor interaction of Interleukin-2, Alpha-Interferon and tumor infiltrating lymphocytes. J Natl Cancer Inst (in press)
Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735
Rubenstein S, Familleti PC, Pestka S (1981) Convenient assay for interferons. J Virol 37:755
Sato N, Goto T, Haranaka K, Santomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y (1986) Actions of tumor necrosis factor on cultured vascular endothelial cells: morphological modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76:1113
Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629
Sobel A, Lagrue G (1980) Role of a vascular permeability-increasing factor released by lymphocytes in renal pathology. Lymphokine Rep 1:211
Sobel AT, Branellec AI, Blanc GJ, Lagrue 5A (1977) Physiochemical characterization of a vascular permeability factor produced by Con A-stimulated human lymphocytes. J Immunol 119:1230
Shasby DM, Van Benthuyson KM, Tate RM, Shasby SS, McMutry I, Repine JE (1982) Granulocytes mediate acute edematous lung injury in rabbits and in isolated rabbit lung perfused with phorbol myristate acetate. Role of O2 radicals. Am Rev Respir Dis 125:443
Suttless J, Schwasting JA, Strout RD (1986) Flow cytometric analysis reveals the presence of asialo GM1 on the surface membranes of alloimmune cytotoxic T-lymphocytes. J Immunol 136:1586
Utsugi T, Sonc S (1986) Comparative analysis of the priming effect of human interferon-γ, α, and β on synergism with muranyl dipeptide analog for anti tumor expression of human blood monocytes. J Immunol 136:1117
Van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J (1987) Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75–1) and sensitizes them to anti-proliferative effects of tamoxifen. Br J Cancer 55:255
Wan YJ, Orrison BM, Lieberman R, Lazarovici P, Ozato K (1987) Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells. J Cell Physiol 130:276
Weiss SJ, Regiani S (1983) Neutrophils degrade subendothelial matrices in the presence of alpha-1-proteinase inhibitor: Cooperative use of lysosomal proteinases and oxygen metabolites. J Clin Invest 73:1297
Wor Then GS, Goins AJ, Mitchel BC, Larson GL, Reeves JR, Henson PM (1983) Platelet activating factor causes neutrophil accumulation and edema in rabbit lungs. Chest 83: 13 S
Yang JC, Mulle JJ, Rosenberg SA (1986) Murine lymphokine-activated killer (LAK) cells. Phenotypic characterization of the precursor and effector cells. J Immunol 137:715
Author information
Authors and Affiliations
Additional information
Abbreviations used: LAK, lymphokine-activated killer; IFN, interferon; TNF, tumor necrosis factor; IL-2, interleukin-2
Rights and permissions
About this article
Cite this article
Puri, R.K., Rosenberg, S.A. Combined effects of interferon α and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother 28, 267–274 (1989). https://doi.org/10.1007/BF00205236
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205236